CSPC's GLP-1 Targeted Drug Project Approved as a Major Technology Innovation Project

Recently, the Shandong Provincial Department of Science and Technology issued a "Notice on Allocating Projects for Shandong Province's Key Research and Development Programs (Major Technology Innovation Projects) for the Year 2023". The project titled "Key Technology Research for the Industrialization of Recombinant Glucagon-Like Peptide-1 (GLP-1) Fc Fusion Protein Injection (TG103 Project)", which has been undertaken by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (referred to as "CSPC Baike"), has been approved and received financial support from the provincial government.

Shandong province's key research and development programs (major technology innovation projects) are organized and led by the Shandong Provincial Department of Science and Technology, with all projects being managed through an open competition mechanism and military-pledge-style management. Since 2022, CSPC Baike has established a dedicated project application team, collaborated across multiple disciplines to complete the necessary documentation, and successfully navigated through multiple stages, including systematic submission, formal review, and on-site inspections to secure project approval.

TG103 is an innovative recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein injection. The project has been approved for clinical trials in indications including type 2 diabetes, overweight/obesity, non-alcoholic steatohepatitis, and Alzheimer's disease. Phase II clinical trials for type 2 diabetes and overweight/obesity indications have already been completed. TG103 has the advantage of an ultra-long dosing interval of once every two weeks, making it a promising option for patients in the fields of diabetes and weight management in the near future.